Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Revenues:
Products, net	$ 166,911	$ 121,429	$ 433,676	$ 333,221
Type of Revenue [Extensible List]	us-gaap:ProductMember	us-gaap:ProductMember	us-gaap:ProductMember	us-gaap:ProductMember
Collaboration	$ 22,495	$ 22,495	$ 66,750	$ 61,740
Total revenues	189,406	143,924	500,426	394,961
Cost and expenses:
Cost of sales (excluding amortization of in-licensed rights)	23,444	15,015	65,305	40,978
Research and development	139,115	190,438	573,886	515,104
Selling, general and administrative	61,127	75,373	204,605	231,829
Settlement and license charges			10,000
Amortization of in-licensed rights	178	166	527	497
Total cost and expenses	223,864	280,992	854,323	788,408
Operating loss	(34,458)	(137,068)	(353,897)	(393,447)
Other (loss) income:
Gain (loss) on contingent consideration, net	7,200	(45,000)	7,200	(45,000)
Other expense, net	(20,649)	(14,335)	(52,362)	(34,202)
Gain from sale of Priority Review Voucher			102,000	108,069
Total other (loss) income	(13,449)	(59,335)	56,838	28,867
Loss before income tax expense (benefit)	(47,907)	(196,403)	(297,059)	(364,580)
Income tax expense (benefit)	237	96	(260)	231
Net loss	(48,144)	(196,499)	(296,799)	(364,811)
Other comprehensive loss:
Unrealized losses on investments, net of tax	(22)	(12)	(23)	(56)
Total other comprehensive loss	(22)	(12)	(23)	(56)
Comprehensive loss	$ (48,166)	$ (196,511)	$ (296,822)	$ (364,867)
Net loss per share - basic and diluted	$ (0.60)	$ (2.50)	$ (3.72)	$ (4.70)
Weighted average number of shares of common stock used in computing basic and diluted net loss per share	79,880	78,501	79,695	77,637